Dr. Jared Hassler Provides Perspective to Consultant Live on Significance and Impact of FDA’s Approval of Drug for Treatment of Adults with Ultra-Rare Kidney Disease

Jared R. Hassler, MD, Associate Professor of Pathology and Laboratory Medicine at the Lewis Katz School of Medicine at Temple University, provided perspective to Consultant Live on the significance and impact of the U.S. Food and Drug Administration’s approval of Novartis’ oral iptacopan (Fabhalta) for the treatment of adults with C3 glomerulopathy, or C3G. This is the first FDA-approved drug for patients with the ultra-rare kidney disease.